Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
23 participants
Study Classification
INTERVENTIONAL
Study Start Date
2010-11-30
Study Completion Date
2012-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this clinical research study is to learn if SB939 can help to control myelofibrosis. The safety of this drug will also be studied.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
LBH589 (Panobinostat) for the Treatment of Myelofibrosis
NCT01298934
Primary Myelofibrosis
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
Post-Essential Thrombocythemia Related Myelofibrosis
UNKNOWN
PHASE1/PHASE2
A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis
NCT00931762
Primary Myelofibrosis
Post-Polycythemia Vera
Post-Essential Thrombocytopenia
TERMINATED
PHASE2
SB1518 for Patients With Myelodysplastic Syndrome (MDS)
NCT01436084
Leukemia
TERMINATED
PHASE2
Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis
NCT02784496
Myelofibrosis
COMPLETED
PHASE2
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
NCT01969838
Primary Myelofibrosis
Post-Polycythemia Vera Myelofibrosis
Post-Essential Thrombocythemia Myelofibrosis
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The Study Drug:
SB939 is designed to change the DNA (genetic material) of cancer cells. This may keep the cells from growing and cause them to die.
This is the first study in which SB939 is given to patients with myelofibrosis.
Study Drug Administration:
If you are found to be eligible to take part in this study, you will take SB939 by mouth 3 times a week for the first 3 weeks of every 4-week cycle. In some cases, the study doctor may decide your dose can be raised sometime after Cycle 1.
SB939 can be taken at any time of day, 2 hours before or 2 hours after a meal. You should take SB939 at about the same time each day. Do not open, break, or chew the capsules.
If you have any side effects, the doctor may change the amount or how often you take SB939.
You will fill out a study drug diary to keep track of your SB939 doses. You should bring the diary and all used and unused bottles of study drug with you to every study visit.
Study Visits:
At every study visit, you will be asked about any side effects you have had and any drugs you may be taking.
On Day 1 of Cycle 1 (+/- 3 days):
* You will have a physical exam, including measurement of your vital signs.
* You will be asked about any blood transfusions you have had and drugs you have taken since the last visit.
* Your performance status will be recorded.
* Blood (about 4 teaspoons) will be drawn for routine tests.
* You will have an ECG before taking this medication, about 10 minutes after taking medication, and 4-6 hours after taking medication.
On Day 8 of Cycle 1 (+1-3 days), blood (about 2 teaspoons) will be drawn for routine tests.
On Day 15 of Cycle 1 (+/- 3 days):
* You will have a physical exam, including measurement of your vital signs.
* Blood (about 4 teaspoons) will be drawn for routine tests.
* You will have an ECG before taking this medication, about 10 minutes after taking medication, and 4-6 hours after taking medication.
On Day 22 of Cycle 1 (+1-3 days), blood (about 2 teaspoons) will be drawn for routine tests.
On Day 1 of Cycles 2 and 3 (+/- 3 days):
* You will have a physical exam, including measurement of your vital signs.
* You will be asked about any blood transfusions you have had since the last visit.
* Your performance status will be recorded.
* Blood (about 4 teaspoons) will be drawn for routine tests.
* You will have an ECG.
On Day 1 of Cycles 4 and beyond (+/- 3 days), or every 3 cycles starting on Day 1 of Cycle 6 (+/- 3 days) if the doctor decides your schedule can change (if you have not had serious side effects):
* You will have a physical exam, including measurement of your vital signs.
* You will be asked about any blood transfusions you have had and drugs you have taken since the last visit.
* Your performance status will be recorded.
* Blood (about 4 teaspoons) will be drawn for routine tests.
* You will have a bone marrow biopsy and aspiration to check the status of the disease, if the doctor thinks it is needed.
* You will have an ECG at every visit to MD Anderson.
If your study visit schedule is changed to every 3 cycles (Day 1 of Cycles 6, 9, and so on), blood (about 4 teaspoons) will be drawn for routine tests every 28 days (+/- 3 days). These tests will be done at your local doctor's office. Every 28 days (+/- 3 days), the study staff will also call you to ask how you are doing and if you have had any side effects.
You may have additional bone marrow biopsies and aspirations and ECGs any time the doctor thinks it is needed. The study visits may also occur more often than described above, if the doctor thinks it is needed.
Length of Study:
You may continue taking the study drug for as long as the doctor thinks it is in your best interest. You will no longer be able to take the study drug if the disease gets worse, if intolerable side effects occur, or if you need radiation therapy, surgery, or other chemotherapy.
Your participation on the study will be over once you have completed the end-of-treatment visit and follow-up.
End-of-Treatment Visit:
After you stop taking the study drug for any reason, the following tests and procedures will be performed:
* You will have a physical exam, including measurement of your vital signs.
* You will be asked about any blood transfusions you have had and drugs you have taken since the last visit.
* Your performance status will be recorded.
* Blood (about 4 teaspoons) will be drawn for routine tests.
* You will have a bone marrow biopsy and aspiration to check the status of the disease, if the doctor thinks it is needed.
Follow-up:
The study staff will call you 30 days and 60 days after your last dose of the study drug (+/- 3 days). You will be asked how you are doing and if you have had any side effects.
If you have any side effects within 60 days after you stop taking the study drug, you may have extra tests and procedures. For example, blood (about 2 teaspoons) may be drawn for routine tests. If you are still having side effects, the study staff will continue calling you to ask how you are doing until the side effects get better. The schedule for how often you are called will depend on the side effects.
This is an investigational study. SB939 is not FDA approved or commercially available. It is currently being used for research purposes only.
Up to 41 patients will take part in this study. All will be enrolled at the University of Texas (UT) MD Anderson Cancer Center.
SB939 is designed to change the DNA (genetic material) of cancer cells. This may keep the cells from growing and cause them to die.
This is the first study in which SB939 is given to patients with myelofibrosis.
Study Drug Administration:
If you are found to be eligible to take part in this study, you will take SB939 by mouth 3 times a week for the first 3 weeks of every 4-week cycle. In some cases, the study doctor may decide your dose can be raised sometime after Cycle 1.
SB939 can be taken at any time of day, 2 hours before or 2 hours after a meal. You should take SB939 at about the same time each day. Do not open, break, or chew the capsules.
If you have any side effects, the doctor may change the amount or how often you take SB939.
You will fill out a study drug diary to keep track of your SB939 doses. You should bring the diary and all used and unused bottles of study drug with you to every study visit.
Study Visits:
At every study visit, you will be asked about any side effects you have had and any drugs you may be taking.
On Day 1 of Cycle 1 (+/- 3 days):
* You will have a physical exam, including measurement of your vital signs.
* You will be asked about any blood transfusions you have had and drugs you have taken since the last visit.
* Your performance status will be recorded.
* Blood (about 4 teaspoons) will be drawn for routine tests.
* You will have an ECG before taking this medication, about 10 minutes after taking medication, and 4-6 hours after taking medication.
On Day 8 of Cycle 1 (+1-3 days), blood (about 2 teaspoons) will be drawn for routine tests.
On Day 15 of Cycle 1 (+/- 3 days):
* You will have a physical exam, including measurement of your vital signs.
* Blood (about 4 teaspoons) will be drawn for routine tests.
* You will have an ECG before taking this medication, about 10 minutes after taking medication, and 4-6 hours after taking medication.
On Day 22 of Cycle 1 (+1-3 days), blood (about 2 teaspoons) will be drawn for routine tests.
On Day 1 of Cycles 2 and 3 (+/- 3 days):
* You will have a physical exam, including measurement of your vital signs.
* You will be asked about any blood transfusions you have had since the last visit.
* Your performance status will be recorded.
* Blood (about 4 teaspoons) will be drawn for routine tests.
* You will have an ECG.
On Day 1 of Cycles 4 and beyond (+/- 3 days), or every 3 cycles starting on Day 1 of Cycle 6 (+/- 3 days) if the doctor decides your schedule can change (if you have not had serious side effects):
* You will have a physical exam, including measurement of your vital signs.
* You will be asked about any blood transfusions you have had and drugs you have taken since the last visit.
* Your performance status will be recorded.
* Blood (about 4 teaspoons) will be drawn for routine tests.
* You will have a bone marrow biopsy and aspiration to check the status of the disease, if the doctor thinks it is needed.
* You will have an ECG at every visit to MD Anderson.
If your study visit schedule is changed to every 3 cycles (Day 1 of Cycles 6, 9, and so on), blood (about 4 teaspoons) will be drawn for routine tests every 28 days (+/- 3 days). These tests will be done at your local doctor's office. Every 28 days (+/- 3 days), the study staff will also call you to ask how you are doing and if you have had any side effects.
You may have additional bone marrow biopsies and aspirations and ECGs any time the doctor thinks it is needed. The study visits may also occur more often than described above, if the doctor thinks it is needed.
Length of Study:
You may continue taking the study drug for as long as the doctor thinks it is in your best interest. You will no longer be able to take the study drug if the disease gets worse, if intolerable side effects occur, or if you need radiation therapy, surgery, or other chemotherapy.
Your participation on the study will be over once you have completed the end-of-treatment visit and follow-up.
End-of-Treatment Visit:
After you stop taking the study drug for any reason, the following tests and procedures will be performed:
* You will have a physical exam, including measurement of your vital signs.
* You will be asked about any blood transfusions you have had and drugs you have taken since the last visit.
* Your performance status will be recorded.
* Blood (about 4 teaspoons) will be drawn for routine tests.
* You will have a bone marrow biopsy and aspiration to check the status of the disease, if the doctor thinks it is needed.
Follow-up:
The study staff will call you 30 days and 60 days after your last dose of the study drug (+/- 3 days). You will be asked how you are doing and if you have had any side effects.
If you have any side effects within 60 days after you stop taking the study drug, you may have extra tests and procedures. For example, blood (about 2 teaspoons) may be drawn for routine tests. If you are still having side effects, the study staff will continue calling you to ask how you are doing until the side effects get better. The schedule for how often you are called will depend on the side effects.
This is an investigational study. SB939 is not FDA approved or commercially available. It is currently being used for research purposes only.
Up to 41 patients will take part in this study. All will be enrolled at the University of Texas (UT) MD Anderson Cancer Center.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Myeloproliferative Disorders
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SB939
SB939 starting dose 60 mg by mouth every other day, three times weekly for 3 weeks.
Group Type
EXPERIMENTAL
SB939
Intervention Type
DRUG
Starting dose 60 mg by mouth every other day, three times weekly for 3 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SB939
Starting dose 60 mg by mouth every other day, three times weekly for 3 weeks.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Must be equal to or greater than 18 years of age
2. Must be diagnosed with Primary Myelofibrosis (PMF) or Post-Essential Thrombocythemia (ET) Myelofibrosis (MF) Post-Polycythemia Vera (PV) MF with intermediate-1, intermediate -2 or high risk disease according to the International Working Group (IWG) prognostic scoring system, or if with low risk disease then with symptomatic splenomegaly that is equal to or greater than 5 cm below left costal margin by physical exam.
3. Must have adequate organ function as demonstrated by the following: • alanine aminotransferase (ALT) (SGOT) and/or aspartate aminotransferase (AST) (SGPT) equal to or less than 2.5 times upper limit of normal (ULN), \[unless upon judgment of the treating physician, it is believed to be due to extramedullary hematopoiesis (EMH) related to MF\] • Total bilirubin equal to or less than 1.5 times ULN • Serum creatinine equal to or less than 2.5 mg/dL
4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2
5. At least 2 weeks from prior MF-directed treatment (till the start of study drug)
6. Treatment-related toxicities from prior therapies must have resolved to Grade equal to or less than 1
7. No other active malignancies.
8. Females of childbearing potential (a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)).must have negative pregnancy test.
2. Must be diagnosed with Primary Myelofibrosis (PMF) or Post-Essential Thrombocythemia (ET) Myelofibrosis (MF) Post-Polycythemia Vera (PV) MF with intermediate-1, intermediate -2 or high risk disease according to the International Working Group (IWG) prognostic scoring system, or if with low risk disease then with symptomatic splenomegaly that is equal to or greater than 5 cm below left costal margin by physical exam.
3. Must have adequate organ function as demonstrated by the following: • alanine aminotransferase (ALT) (SGOT) and/or aspartate aminotransferase (AST) (SGPT) equal to or less than 2.5 times upper limit of normal (ULN), \[unless upon judgment of the treating physician, it is believed to be due to extramedullary hematopoiesis (EMH) related to MF\] • Total bilirubin equal to or less than 1.5 times ULN • Serum creatinine equal to or less than 2.5 mg/dL
4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2
5. At least 2 weeks from prior MF-directed treatment (till the start of study drug)
6. Treatment-related toxicities from prior therapies must have resolved to Grade equal to or less than 1
7. No other active malignancies.
8. Females of childbearing potential (a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)).must have negative pregnancy test.
Exclusion Criteria
1. Prolongation of the QTc interval to \>470 msec at baseline ECG
2. Known positive status for HIV, or known active hepatitis A, B, or C infection.
3. Any serious medical condition or psychiatric illness that would prevent, (as judged by the treating physician) the subject from signing the informed consent form or any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
4. Pregnant or lactating females.
5. Current use of drugs known to prolong QTc interval.
2. Known positive status for HIV, or known active hepatitis A, B, or C infection.
3. Any serious medical condition or psychiatric illness that would prevent, (as judged by the treating physician) the subject from signing the informed consent form or any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
4. Pregnant or lactating females.
5. Current use of drugs known to prolong QTc interval.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
S*BIO
INDUSTRY
Sponsor Role
collaborator
M.D. Anderson Cancer Center
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alfonso Quintas-Cardama, MD
Role: PRINCIPAL_INVESTIGATOR
UT MD Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UT MD Anderson Cancer Center
Houston, Texas, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Quintas-Cardama A, Kantarjian H, Estrov Z, Borthakur G, Cortes J, Verstovsek S. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res. 2012 Sep;36(9):1124-7. doi: 10.1016/j.leukres.2012.03.003. Epub 2012 Apr 2.
Reference Type
RESULT
Related Links
Access external resources that provide additional context or updates about the study.
http://www.mdanderson.org
UT MD Anderson Cancer Center official website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010-0319
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies
NCT00719836
COMPLETED
PHASE1/PHASE2
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
NCT02124746
COMPLETED
PHASE2
A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis
NCT02584777
WITHDRAWN
PHASE2
Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts
NCT05005182
TERMINATED
PHASE2
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
NCT00724334
COMPLETED
PHASE1/PHASE2
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
NCT05280509
RECRUITING
PHASE1/PHASE2
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
NCT00255346
COMPLETED
PHASE2
Ruxolitinib in Patients With Myelofibrosis
NCT05762874
UNKNOWN
A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With Myelofibrosis
NCT06909136
RECRUITING
PHASE1/PHASE2
Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
NCT01423058
COMPLETED
PHASE1/PHASE2
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
NCT06986174
RECRUITING
PHASE2
A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
NCT05714072
RECRUITING
PHASE1
Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
NCT04878003
RECRUITING
PHASE2
Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
NCT00935987
COMPLETED
PHASE1/PHASE2
A Phase 2 Study With IPI-926 in Patients With Myelofibrosis
NCT01371617
COMPLETED
PHASE2
Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia
NCT07192237
NOT_YET_RECRUITING
PHASE2
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
NCT04562870
ACTIVE_NOT_RECRUITING
PHASE2
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
NCT00098826
COMPLETED
PHASE1
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
NCT02362035
COMPLETED
PHASE1/PHASE2
Multiple Ascending Dose of BMS-911543
NCT01236352
TERMINATED
PHASE1/PHASE2
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
NCT01773187
TERMINATED
PHASE3
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
NCT04562389
ACTIVE_NOT_RECRUITING
PHASE3
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
NCT04281498
COMPLETED
PHASE2
Decitabine in Treating Patients With Myelofibrosis
NCT00095784
ACTIVE_NOT_RECRUITING
PHASE2